Person · CIK 1365619

Laura Brege

Director at Mirum Pharmaceuticals, Edgewise Therapeutics, Pacira BioSciences and Acadia Pharmaceuticals

Earlier: Portola Pharmaceuticals, Dynavax Technologies, Aratana Therapeutics, Delcath Systems, Onyx Pharmaceuticals and Angiotech Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$17.6M

Noticed on Form 144$2M

Bought on Form 4$125K

Companies10

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Mirum Pharmaceuticals MIRM	Common Stock	Directly	15,703	Sep 11, 2025 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Stock Option (right to buy) exercise $101.00, expires Jun 14, 2036, into Common Stock	Directly	3,772	Jun 15, 2026 · Filing · EDGAR
Mirum Pharmaceuticals MIRM	Deferred Stock Units into Common Stock	Directly	1,980	Jun 15, 2026 · Filing · EDGAR
Edgewise Therapeutics EWTX	Stock Option (Right to Buy) exercise $35.59, expires Jun 5, 2036, into Common Stock	Directly	16,377	Jun 5, 2026 · Filing · EDGAR
Pacira BioSciences PCRX	Common Stock	Directly	30,120	Jun 10, 2026 · Filing · EDGAR
Pacira BioSciences PCRX	Stock Option (Right to Buy) exercise $23.42, expires Jun 10, 2036, into Common Stock	Directly	10,891	Jun 10, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACAD	Common Stock	Directly	23,202	May 29, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACAD	Director Stock Options (Right to Buy) exercise $21.66, expires May 28, 2036, into Common Stock	Directly	16,004	May 29, 2026 · Filing · EDGAR
Acadia Pharmaceuticals ACAD	Restricted Stock Units into Common Stock	Directly	9,311	May 29, 2026 · Filing · EDGAR
Aratana Therapeutics	Common Stock	Directly	13,500	Jul 27, 2018 · Filing · EDGAR
Aratana Therapeutics	Stock Option (Right to Buy) exercise $4.36, expires Jul 26, 2028, into Common Stock	Directly	7,500	Jul 27, 2018 · Filing · EDGAR
Delcath Systems	Common Stock	Directly	11,678	Jul 7, 2014 · Filing · EDGAR
Onyx Pharmaceuticals	Common Stock	Directly	39,670	Oct 14, 2011 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q3 2025	$1.3M	$1.3M	—
Q2 2025	$315K	$315K	—
Q3 2024	—	—	$13K
Q2 2023	$420K	$421K	—
Q1 2023	$228K	Not machine-readable	—
Q4 2020	$791K	Not machine-readable	—
Q2 2020	$102K	Not machine-readable	—
Q1 2020	$422K	Not machine-readable	—
Q3 2019	—	—	$112K
Q1 2019	$200K	Not machine-readable	—
Q1 2018	$752K	Not machine-readable	—
Q2 2016	$47K	Not machine-readable	—
Q1 2015	$336K	Not machine-readable	—
Q3 2014	$281K	Not machine-readable	—
Q2 2014	$1.1M	Not machine-readable	—
Q1 2014	$242K	Not machine-readable	—
Q4 2013	$1.2M	Not machine-readable	—
Q3 2013	$1.1M	Not machine-readable	—
Q4 2011	$360K	Not machine-readable	—
Q3 2011	$350K	Not machine-readable	—
Q2 2011	$595K	Not machine-readable	—
Q1 2011	$445K	Not machine-readable	—
Q4 2010	$750K	Not machine-readable	—
Q2 2010	$510K	Not machine-readable	—
Q1 2010	$477K	Not machine-readable	—
Q4 2009	$375K	Not machine-readable	—
Q3 2009	$898K	Not machine-readable	—
Q2 2009	$149K	Not machine-readable	—
Q1 2009	$410K	Not machine-readable	—
Q4 2008	$375K	Not machine-readable	—
Q3 2008	$469K	Not machine-readable	—
Q2 2008	$481K	Not machine-readable	—
Q1 2008	$636K	Not machine-readable	—
Q3 2007	$1.6M	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Sep 11, 2025	17,000 · ~$1.3M	Sep 11, 2025	Sold as noticed Sold 17,000 in 2 sales, Sep 11 to Sep 11 · $1.3M Form 4	Filing · EDGAR
Acadia Pharmaceuticals ACAD · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Jun 4, 2025	14,446 · ~$315K	Jun 4, 2025	Sold as noticed Sold 14,446 at $21.78 on Jun 4 · $315K Form 4	Filing · EDGAR
Acadia Pharmaceuticals ACAD · Piper Sandler · 10b5-1 plan adopted Nov 14, 2022 · 1 notice
Jun 12, 2023	4,500 · ~$112K	Jun 12, 2023	Sold as noticed Sold 4,500 at $24.87 on Jun 12 · $112K Form 4	Filing · EDGAR
Pacira BioSciences PCRX · Fidelity Brokerage Services · 10b5-1 plan adopted Nov 4, 2022 · 2 notices
Jun 5, 2023	600 · ~$23K	Jun 5, 2023	Sold as noticed Sold 600 at $38.74 on Jun 5 · $23K Form 4	Filing · EDGAR
Apr 3, 2023	7,000 · ~$285K	Apr 3, 2023	Sold as noticed Sold 7,000 at $40.72 on Apr 3 · $285K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 57 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 12,500 at $18.25 on Jan 12, 2023 · $228K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira BioSciences (PCRX): Sold 12,000 at $65.95 on Nov 16, 2020 · $791K	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira BioSciences (PCRX): Sold 2,100 at $48.70 on Jun 5, 2020 · $102K	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 10,000 at $42.19 on Jan 7, 2020 · $422K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 10,000 at $20.00 on Jan 9, 2019 · $200K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 25,000 at $30.06 on Jan 2, 2018 · $752K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira BioSciences (PCRX): Sold 1,000 at $46.95 on Jun 6, 2016 · $47K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 10,000 at $33.63 on Feb 11, 2015 · $336K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 10,000 at $28.07 on Sep 15, 2014 · $281K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira BioSciences (PCRX): Sold 2,500 at $74.67 on May 9, 2014 · $187K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Pacira BioSciences (PCRX): Sold 7,500 at $73.57 on May 9, 2014 · $552K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 14,285 at $22.54 on Apr 4, 2014 · $322K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 10,000 at $24.18 on Jan 15, 2014 · $242K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 44,117 at $23.41 on Dec 10, 2013 · $1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 10,000 at $21.63 on Oct 10, 2013 · $216K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Acadia Pharmaceuticals (ACAD): Sold 46,153 at $22.80 on Sep 10, 2013 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 10,000 at $36.01 on Oct 14, 2011 · $360K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 10,000 at $35.00 on Jul 14, 2011 · $350K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,000 at $35.01 on Apr 26, 2011 · $70K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 8,000 at $35.00 on Apr 26, 2011 · $280K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 7,000 at $35.02 on Apr 1, 2011 · $245K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $35.64 on Jan 18, 2011 · $445K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 25,000 at $30.00 on Nov 8, 2010 · $750K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 900 at $30.34 on Apr 15, 2010 · $27K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 11,600 at $30.40 on Apr 15, 2010 · $353K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 4,334 at $30.10 on Apr 1, 2010 · $130K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 3,333 at $30.15 on Mar 31, 2010 · $100K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $30.12 on Jan 15, 2010 · $377K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $30.00 on Dec 2, 2009 · $375K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 25,000 at $35.90 on Jul 22, 2009 · $898K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 5,333 at $27.90 on Apr 1, 2009 · $149K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $32.81 on Jan 15, 2009 · $410K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $30.00 on Nov 7, 2008 · $375K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $37.50 on Jul 15, 2008 · $469K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $33.22 on Apr 15, 2008 · $415K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,142 at $30.87 on Apr 2, 2008 · $66K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 12,500 at $50.89 on Jan 15, 2008 · $636K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 19,608 at $31.25 on Aug 10, 2007 · $613K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 800 at $31.26 on Aug 10, 2007 · $25K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,200 at $31.27 on Aug 10, 2007 · $69K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 200 at $31.28 on Aug 10, 2007 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 200 at $31.28 on Aug 10, 2007 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 100 at $31.29 on Aug 10, 2007 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,500 at $31.30 on Aug 10, 2007 · $47K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 100 at $31.31 on Aug 10, 2007 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,900 at $31.37 on Aug 10, 2007 · $60K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 100 at $31.38 on Aug 10, 2007 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 3,500 at $31.40 on Aug 10, 2007 · $110K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 400 at $31.49 on Aug 10, 2007 · $13K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 100 at $31.51 on Aug 10, 2007 · $3K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 11,092 at $31.50 on Aug 10, 2007 · $349K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 2,600 at $31.53 on Aug 10, 2007 · $82K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 300 at $31.56 on Aug 10, 2007 · $9K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 200 at $31.58 on Aug 10, 2007 · $6K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 400 at $31.57 on Aug 10, 2007 · $13K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 3,700 at $31.61 on Aug 10, 2007 · $117K	Filing · EDGAR
—	—	—	Notice not machine-readable Onyx Pharmaceuticals: Sold 1,000 at $31.64 on Aug 10, 2007 · $32K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Mirum Pharmaceuticals MIRM Director · filings 2019 to 2026 · sold $1.3M · bought $112K · $1.3M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 15, 2026	Grant or award from the company Stock Option (right to buy)	+3,772			3,772 direct	Filing · EDGAR
Jun 15, 2026	Grant or award from the company Deferred Stock Units	+1,980			1,980 direct	Filing · EDGAR
Sep 11, 2025	Option or RSU exercised or converted	+17,000	$15.00	$255K	32,703 direct	Filing · EDGAR
Sep 11, 2025	Open-market or private sale	−15,509	$74.34	$1.2M	17,194 direct	Filing · EDGAR
Sep 11, 2025	Open-market or private sale	−1,491	$75.07	$112K	15,703 direct	Filing · EDGAR
Sep 11, 2025	Option or RSU exercised or converted Stock Option (right to buy)	−17,000			0 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted	+5,703			15,703 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted Restricted Stock Units	−5,703			0 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Stock Option (right to buy)	+6,268			6,268 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Deferred Stock Units	+3,977			3,977 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Stock Option (right to buy)	+8,779			8,779 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Restricted Stock Units	+5,703			5,703 direct	Filing · EDGAR
Jun 12, 2023	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 4, 2021	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 11, 2020	Grant or award from the company Stock Option (right to buy)	+14,167			14,167 direct	Filing · EDGAR
Sep 10, 2019	Open-market or private purchase	+10,000	$11.22	$112K	10,000 direct	Filing · EDGAR
Jul 17, 2019	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR

Edgewise Therapeutics EWTX Director · filings 2021 to 2026

Date	Transaction	Shares	Held after	Source
Jun 5, 2026	Grant or award from the company Stock Option (Right to Buy)	+16,377	16,377 direct	Filing · EDGAR
Jun 16, 2025	Grant or award from the company Stock Option (Right to Buy)	+30,000	30,000 direct	Filing · EDGAR
Jun 10, 2024	Grant or award from the company Stock Option (Right to Buy)	+20,594	20,594 direct	Filing · EDGAR
Jun 12, 2023	Grant or award from the company Stock Option (Right to Buy)	+22,123	22,123 direct	Filing · EDGAR
Jun 24, 2022	Grant or award from the company Stock Option (Right to Buy)	+42,087	42,087 direct	Filing · EDGAR

Pacira BioSciences PCRX Director · filings 2011 to 2026 · sold $2M · bought $13K · $308K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 10, 2026	Grant or award from the company	+6,405			30,120 direct	Filing · EDGAR
Jun 10, 2026	Grant or award from the company Stock Option (Right to Buy)	+10,891			10,891 direct	Filing · EDGAR
Jun 11, 2025	Grant or award from the company	+6,163			23,715 direct	Filing · EDGAR
Jun 11, 2025	Grant or award from the company Stock Option (Right to Buy)	+11,279			11,279 direct	Filing · EDGAR
Aug 16, 2024	Open-market or private purchase	+1,000	$12.81	$13K	17,552 direct	Filing · EDGAR
Jun 12, 2024	Grant or award from the company	+5,230			16,552 direct	Filing · EDGAR
Jun 12, 2024	Grant or award from the company Stock Option (Right to Buy)	+12,179			12,179 direct	Filing · EDGAR
Jun 14, 2023	Grant or award from the company	+1,775			11,322 direct	Filing · EDGAR
Jun 14, 2023	Grant or award from the company Stock Option (Right to Buy)	+12,925			12,925 direct	Filing · EDGAR
Jun 5, 2023	Sale under a 10b5-1 plan	−600	$38.74	$23K	9,547 direct	Filing · EDGAR
Apr 3, 2023	Option or RSU exercised or converted	+7,000	$29.90	$209K	17,147 direct	Filing · EDGAR
Apr 3, 2023	Sale under a 10b5-1 plan	−7,000	$40.72	$285K	10,147 direct	Filing · EDGAR
Apr 3, 2023	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,000			0 direct	Filing · EDGAR
Jun 8, 2022	Grant or award from the company	+1,160			10,147 direct	Filing · EDGAR
Jun 8, 2022	Grant or award from the company Stock Option (Right to Buy)	+8,225			8,225 direct	Filing · EDGAR
Jun 9, 2021	Grant or award from the company	+1,066			8,987 direct	Filing · EDGAR
Jun 9, 2021	Grant or award from the company Stock Option (Right to Buy)	+7,626			7,626 direct	Filing · EDGAR
Nov 16, 2020	Option or RSU exercised or converted	+12,000	$13.98	$168K	19,921 direct	Filing · EDGAR
Nov 16, 2020	Open-market or private sale	−12,000	$65.95	$791K	7,921 direct	Filing · EDGAR
Nov 16, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,000			0 direct	Filing · EDGAR
Jun 9, 2020	Grant or award from the company	+1,260			7,921 direct	Filing · EDGAR
Jun 9, 2020	Grant or award from the company Stock Option (Right to Buy)	+8,027			8,027 direct	Filing · EDGAR
Jun 5, 2020	Open-market or private sale	−2,100	$48.70	$102K	6,661 direct	Filing · EDGAR
Jun 5, 2019	Grant or award from the company	+4,134			8,761 direct	Filing · EDGAR
Jun 5, 2019	Grant or award from the company Stock Option (Right to Buy)	+8,437			8,437 direct	Filing · EDGAR
Jun 13, 2018	Grant or award from the company	+782			4,627 direct	Filing · EDGAR
Jun 13, 2018	Grant or award from the company Stock Option (Right to Buy)	+4,693			4,693 direct	Filing · EDGAR
Jun 14, 2017	Grant or award from the company	+1,357			3,845 direct	Filing · EDGAR
Jun 14, 2017	Grant or award from the company Stock Option (Right to Buy)	+2,714			2,714 direct	Filing · EDGAR
Jun 15, 2016	Grant or award from the company	+1,488			2,488 direct	Filing · EDGAR
Jun 15, 2016	Grant or award from the company Stock Option (Right to Buy)	+2,975			2,975 direct	Filing · EDGAR
Jun 6, 2016	Sale under a 10b5-1 plan	−1,000	$46.95	$47K	1,000 direct	Filing · EDGAR
Jun 3, 2015	Grant or award from the company	+2,000			2,000 direct	Filing · EDGAR
Jun 3, 2015	Grant or award from the company Stock Option (Right to Buy)	+4,000			4,000 direct	Filing · EDGAR
Jun 3, 2014	Grant or award from the company Stock Option (Right to Buy)	+8,000			8,000 direct	Filing · EDGAR
May 9, 2014	Option or RSU exercised or converted	+7,000	$10.81	$76K	7,000 direct	Filing · EDGAR
May 9, 2014	Option or RSU exercised or converted	+3,000	$13.98	$42K	10,000 direct	Filing · EDGAR
May 9, 2014	Sale under a 10b5-1 plan	−7,500	$73.57	$552K	2,500 direct	Filing · EDGAR
May 9, 2014	Sale under a 10b5-1 plan	−2,500	$74.67	$187K	0 direct	Filing · EDGAR
May 9, 2014	Option or RSU exercised or converted Stock Option (Right to Buy)	−7,000			0 direct	Filing · EDGAR
May 9, 2014	Option or RSU exercised or converted Stock Option (Right to Buy)	−3,000			12,000 direct	Filing · EDGAR
Jun 12, 2013	Grant or award from the company Stock Option (Right to Buy)	+7,000			7,000 direct	Filing · EDGAR
Jun 5, 2012	Grant or award from the company Common Stock	+7,000			7,000 direct	Filing · EDGAR
Jun 2, 2011	Grant or award from the company Stock option (right to buy)	+15,000			15,000 direct	Filing · EDGAR

Acadia Pharmaceuticals ACAD Director · filings 2008 to 2026 · sold $5.5M · $427K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
May 29, 2026	Option or RSU exercised or converted	+8,107			23,202 direct	Filing · EDGAR
May 29, 2026	Option or RSU exercised or converted Restricted Stock Units	−8,107			0 direct	Filing · EDGAR
May 29, 2026	Grant or award from the company Director Stock Options (Right to Buy)	+16,004			16,004 direct	Filing · EDGAR
May 29, 2026	Grant or award from the company Restricted Stock Units	+9,311			9,311 direct	Filing · EDGAR
Jun 4, 2025	Open-market or private sale	−14,446	$21.78	$315K	15,095 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted	+9,387			29,541 direct	Filing · EDGAR
May 29, 2025	Option or RSU exercised or converted Restricted Stock Units	−9,387			0 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Director Stock Options (Right to Buy)	+13,793			13,793 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Restricted Stock Units	+8,107			8,107 direct	Filing · EDGAR
May 29, 2024	Option or RSU exercised or converted	+6,652			20,154 direct	Filing · EDGAR
May 29, 2024	Option or RSU exercised or converted Restricted Stock Units	−6,652			0 direct	Filing · EDGAR
May 29, 2024	Grant or award from the company Director Stock Options (Right to Buy)	+15,959			15,959 direct	Filing · EDGAR
May 29, 2024	Grant or award from the company Restricted Stock Units	+9,387			9,387 direct	Filing · EDGAR
Jun 12, 2023	Sale under a 10b5-1 plan	−4,500	$24.87	$112K	13,502 direct	Filing · EDGAR
Jun 1, 2023	Option or RSU exercised or converted	+8,552			18,002 direct	Filing · EDGAR
Jun 1, 2023	Option or RSU exercised or converted Restricted Stock Units	−8,552			0 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company Director Stock Options (Right to Buy)	+11,045			11,045 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company Restricted Stock Units	+6,652			6,652 direct	Filing · EDGAR
Jan 12, 2023	Option or RSU exercised or converted	+12,500	$17.01	$213K	12,500 direct	Filing · EDGAR
Jan 12, 2023	Sale under a 10b5-1 plan	−12,500	$18.25	$228K	0 direct	Filing · EDGAR
Jan 12, 2023	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			0 direct	Filing · EDGAR
Jun 7, 2022	Option or RSU exercised or converted	+6,391			9,450 direct	Filing · EDGAR
Jun 7, 2022	Option or RSU exercised or converted Restricted Stock Units	−6,391			0 direct	Filing · EDGAR
Jun 7, 2022	Grant or award from the company Director Stock Options (Right to Buy)	+14,368			14,368 direct	Filing · EDGAR
Jun 7, 2022	Grant or award from the company Restricted Stock Units	+8,552			8,552 direct	Filing · EDGAR
Jun 22, 2021	Option or RSU exercised or converted	+3,059			3,059 direct	Filing · EDGAR
Jun 22, 2021	Option or RSU exercised or converted Restricted Stock Units	−3,059			0 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company Director Stock Options (Right to Buy)	+11,637			11,637 direct	Filing · EDGAR
Jun 22, 2021	Grant or award from the company Restricted Stock Units	+6,391			6,391 direct	Filing · EDGAR
Jun 23, 2020	Grant or award from the company Director Stock Options (Right to Buy)	+5,579			5,579 direct	Filing · EDGAR
Jun 23, 2020	Grant or award from the company Restricted Stock Units	+3,059			3,059 direct	Filing · EDGAR
Jan 7, 2020	Option or RSU exercised or converted	+10,000	$1.75	$18K	10,000 direct	Filing · EDGAR
Jan 7, 2020	Sale under a 10b5-1 plan	−10,000	$42.19	$422K	0 direct	Filing · EDGAR
Jan 7, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Jun 26, 2019	Grant or award from the company Stock Option (Right to Buy)	−15,000			15,000 direct	Filing · EDGAR
Jan 9, 2019	Option or RSU exercised or converted	+10,000	$2.16	$22K	10,000 direct	Filing · EDGAR
Jan 9, 2019	Sale under a 10b5-1 plan	−10,000	$20.00	$200K	0 direct	Filing · EDGAR
Jan 9, 2019	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Jun 6, 2018	Grant or award from the company Stock option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jan 2, 2018	Option or RSU exercised or converted	+15,000	$8.06	$121K	15,000 direct	Filing · EDGAR
Jan 2, 2018	Option or RSU exercised or converted	+10,000	$8.49	$85K	25,000 direct	Filing · EDGAR
Jan 2, 2018	Sale under a 10b5-1 plan	−25,000	$30.06	$752K	0 direct	Filing · EDGAR
Jan 2, 2018	Option or RSU exercised or converted Stock option (right to buy)	−15,000			0 direct	Filing · EDGAR
Jan 2, 2018	Option or RSU exercised or converted Stock option (right to buy)	−10,000			0 direct	Filing · EDGAR
Jun 13, 2017	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 10, 2016	Grant or award from the company Stock option (right to buy)	+12,500			12,500 direct	Filing · EDGAR
Jun 15, 2015	Grant or award from the company Stock option (right to buy)	+12,500			12,500 direct	Filing · EDGAR
Feb 11, 2015	Option or RSU exercised or converted	+10,000	$1.75	$18K	10,000 direct	Filing · EDGAR
Feb 11, 2015	Sale under a 10b5-1 plan	−10,000	$33.63	$336K	0 direct	Filing · EDGAR
Feb 11, 2015	Option or RSU exercised or converted Stock option (right to buy)	−10,000			0 direct	Filing · EDGAR
Sep 15, 2014	Option or RSU exercised or converted	+10,000	$1.75	$18K	10,000 direct	Filing · EDGAR
Sep 15, 2014	Sale under a 10b5-1 plan	−10,000	$28.07	$281K	0 direct	Filing · EDGAR
Sep 15, 2014	Option or RSU exercised or converted Stock option (right to buy)	−10,000			10,000 direct	Filing · EDGAR
Jun 6, 2014	Grant or award from the company Stock option (right to buy)	+12,500			12,500 direct	Filing · EDGAR
Apr 4, 2014	Option or RSU exercised or converted	+14,285	$1.75	$25K	14,285 direct	Filing · EDGAR
Apr 4, 2014	Sale under a 10b5-1 plan	−14,285	$22.54	$322K	0 direct	Filing · EDGAR
Apr 4, 2014	Option or RSU exercised or converted Stock option (right to buy)	−14,285			20,000 direct	Filing · EDGAR
Jan 15, 2014	Option or RSU exercised or converted	+10,000	$1.36	$14K	10,000 direct	Filing · EDGAR
Jan 15, 2014	Sale under a 10b5-1 plan	−10,000	$24.18	$242K	0 direct	Filing · EDGAR
Jan 15, 2014	Option or RSU exercised or converted Stock option (right to buy)	−10,000			0 direct	Filing · EDGAR

19 earlier transactions are in the filing list below.

Portola Pharmaceuticals Director · filings 2015 to 2020

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 2, 2020	Returned to the company	−13,194	$18.00	$237K	0 direct	Filing · EDGAR
Jul 2, 2020	Returned to the company	−7,281	$18.00	$131K	0 direct	Filing · EDGAR
Jul 2, 2020	Returned to the company Stock Option (Right to Buy)	−11,377	$0.06	$683	0 direct	Filing · EDGAR
Jul 2, 2020	Returned to the company Stock Option (Right to Buy)	−44,991			0 direct	Filing · EDGAR
Jun 12, 2020	Grant or award from the company	+7,281			20,475 direct	Filing · EDGAR
Jun 12, 2020	Grant or award from the company Stock Option (Right to Buy)	+11,377			11,377 direct	Filing · EDGAR
Jun 13, 2019	Grant or award from the company	+4,194			13,194 direct	Filing · EDGAR
Jun 13, 2019	Grant or award from the company Stock Option (Right to Buy)	+6,991			6,991 direct	Filing · EDGAR
Jun 8, 2018	Grant or award from the company	+3,000			9,000 direct	Filing · EDGAR
Jun 8, 2018	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Jun 16, 2017	Grant or award from the company	+3,000			3,000 direct	Filing · EDGAR
Jun 16, 2017	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Jun 17, 2016	Grant or award from the company	+3,000			3,000 direct	Filing · EDGAR
Jun 17, 2016	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Feb 5, 2015	Grant or award from the company Stock Option (right to buy)	+20,000			20,000 direct	Filing · EDGAR

Dynavax Technologies Director · filings 2015 to 2019

Date	Transaction	Shares	Held after	Source
May 30, 2019	Grant or award from the company Option (Right to Buy)	+15,000	15,000 direct	Filing · EDGAR
May 31, 2018	Grant or award from the company Option (Right to Buy)	+15,000	15,000 direct	Filing · EDGAR
Jun 2, 2017	Grant or award from the company Option (Right to Buy)	+7,500	7,500 direct	Filing · EDGAR
May 31, 2016	Grant or award from the company Option (Right to Buy)	+7,500	7,500 direct	Filing · EDGAR
Oct 13, 2015	Grant or award from the company Option (Right to Buy)	+8,800	8,800 direct	Filing · EDGAR
May 27, 2015	Grant or award from the company Option (Right to Buy)	+1,875	1,875 direct	Filing · EDGAR
Feb 5, 2015	Grant or award from the company Option (right to buy)	−2,000	2,000 direct	Filing · EDGAR

Aratana Therapeutics Director · filings 2014 to 2018

Date	Transaction	Shares	Held after	Source
Jul 27, 2018	Grant or award from the company	+4,500	13,500 direct	Filing · EDGAR
Jul 27, 2018	Grant or award from the company Stock Option (Right to Buy)	+7,500	7,500 direct	Filing · EDGAR
Jun 21, 2017	Grant or award from the company	+4,500	9,000 direct	Filing · EDGAR
Jun 21, 2017	Grant or award from the company Stock Option (Right to Buy)	+7,500	7,500 direct	Filing · EDGAR
Jun 24, 2016	Grant or award from the company	+4,500	4,500 direct	Filing · EDGAR
Jun 24, 2016	Grant or award from the company Stock Option (Right to Buy)	+7,500	7,500 direct	Filing · EDGAR
Jun 18, 2015	Grant or award from the company Stock Option (Right to Buy)	+10,000	10,000 direct	Filing · EDGAR
Feb 5, 2014	Grant or award from the company Stock Option (Right to Buy)	+13,237	13,237 direct	Filing · EDGAR

Delcath Systems Director · filings 2012 to 2014

Date	Transaction	Shares	Held after	Source
Jul 7, 2014	Grant or award from the company	+9,616	11,678 direct	Filing · EDGAR
Jun 5, 2013	Grant or award from the company	+33,000	33,000 direct	Filing · EDGAR
Jul 6, 2012	Grant or award from the company Stock Option (right to buy)	+54,586	54,586 direct	Filing · EDGAR

Onyx Pharmaceuticals EVP, Corporate Affairs · filings 2006 to 2011 · sold $8.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 14, 2011	Option or RSU exercised or converted	+5,904	$15.44	$91K	45,574 direct	Filing · EDGAR
Oct 14, 2011	Option or RSU exercised or converted	+4,096	$24.84	$102K	49,670 direct	Filing · EDGAR
Oct 14, 2011	Sale under a 10b5-1 plan	−10,000	$36.01	$360K	39,670 direct	Filing · EDGAR
Oct 14, 2011	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,904			36,596 direct	Filing · EDGAR
Oct 14, 2011	Option or RSU exercised or converted Stock Option (Right to Buy)	−4,096			65,904 direct	Filing · EDGAR
Jul 14, 2011	Option or RSU exercised or converted	+10,000	$15.44	$154K	49,427 direct	Filing · EDGAR
Jul 14, 2011	Sale under a 10b5-1 plan	−10,000	$35.00	$350K	39,427 direct	Filing · EDGAR
Jul 14, 2011	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			42,500 direct	Filing · EDGAR
Apr 26, 2011	Option or RSU exercised or converted	+10,000	$15.44	$154K	49,427 direct	Filing · EDGAR
Apr 26, 2011	Sale under a 10b5-1 plan	−8,000	$35.00	$280K	41,427 direct	Filing · EDGAR
Apr 26, 2011	Sale under a 10b5-1 plan	−2,000	$35.01	$70K	39,427 direct	Filing · EDGAR
Apr 26, 2011	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			52,500 direct	Filing · EDGAR
Apr 1, 2011	Sale under a 10b5-1 plan	−7,000	$35.02	$245K	39,427 direct	Filing · EDGAR
Mar 31, 2011	Grant or award from the company	+5,000			23,927 direct	Filing · EDGAR
Mar 31, 2011	Grant or award from the company	+22,500			46,427 direct	Filing · EDGAR
Mar 31, 2011	Grant or award from the company Stock Option (Right to Buy)	+35,000			35,000 direct	Filing · EDGAR
Jan 18, 2011	Option or RSU exercised or converted	+12,500	$15.44	$193K	31,427 direct	Filing · EDGAR
Jan 18, 2011	Sale under a 10b5-1 plan	−12,500	$35.64	$445K	18,927 direct	Filing · EDGAR
Jan 18, 2011	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			62,500 direct	Filing · EDGAR
Nov 8, 2010	Option or RSU exercised or converted	+25,000	$15.44	$386K	43,514 direct	Filing · EDGAR
Nov 8, 2010	Sale under a 10b5-1 plan	−25,000	$30.00	$750K	18,514 direct	Filing · EDGAR
Nov 8, 2010	Option or RSU exercised or converted Stock Option (Right to Buy)	−25,000			75,000 direct	Filing · EDGAR
Apr 15, 2010	Option or RSU exercised or converted	+12,500	$15.44	$193K	30,626 direct	Filing · EDGAR
Apr 15, 2010	Sale under a 10b5-1 plan	−11,600	$30.40	$353K	19,026 direct	Filing · EDGAR
Apr 15, 2010	Sale under a 10b5-1 plan	−900	$30.34	$27K	18,126 direct	Filing · EDGAR
Apr 15, 2010	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			100,000 direct	Filing · EDGAR
Apr 1, 2010	Sale under a 10b5-1 plan	−4,334	$30.10	$130K	18,126 direct	Filing · EDGAR
Mar 31, 2010	Grant or award from the company	+8,000			25,793 direct	Filing · EDGAR
Mar 31, 2010	Sale under a 10b5-1 plan	−3,333	$30.15	$100K	22,460 direct	Filing · EDGAR
Mar 31, 2010	Grant or award from the company Stock Option (RIght to Buy)	+56,000			56,000 direct	Filing · EDGAR
Jan 15, 2010	Option or RSU exercised or converted	+12,500	$15.44	$193K	30,293 direct	Filing · EDGAR
Jan 15, 2010	Sale under a 10b5-1 plan	−12,500	$30.12	$377K	17,793 direct	Filing · EDGAR
Jan 15, 2010	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			112,500 direct	Filing · EDGAR
Dec 2, 2009	Option or RSU exercised or converted	+12,500	$15.44	$193K	30,016 direct	Filing · EDGAR
Dec 2, 2009	Sale under a 10b5-1 plan	−12,500	$30.00	$375K	17,516 direct	Filing · EDGAR
Dec 2, 2009	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			125,000 direct	Filing · EDGAR
Jul 22, 2009	Option or RSU exercised or converted	+25,000	$15.44	$386K	42,516 direct	Filing · EDGAR
Jul 22, 2009	Sale under a 10b5-1 plan	−25,000	$35.90	$898K	17,516 direct	Filing · EDGAR
Jul 22, 2009	Option or RSU exercised or converted Stock Option (Right to Buy)	−25,000			137,500 direct	Filing · EDGAR
Apr 1, 2009	Sale under a 10b5-1 plan	−5,333	$27.90	$149K	17,241 direct	Filing · EDGAR
Mar 31, 2009	Grant or award from the company	+7,000			22,574 direct	Filing · EDGAR
Mar 31, 2009	Grant or award from the company Stock Option (Right to Buy)	+49,000			49,000 direct	Filing · EDGAR
Jan 15, 2009	Option or RSU exercised or converted	+12,500	$15.44	$193K	28,074 direct	Filing · EDGAR
Jan 15, 2009	Sale under a 10b5-1 plan	−12,500	$32.81	$410K	15,574 direct	Filing · EDGAR
Jan 15, 2009	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			162,500 direct	Filing · EDGAR
Nov 7, 2008	Option or RSU exercised or converted	+12,500	$15.44	$193K	27,930 direct	Filing · EDGAR
Nov 7, 2008	Sale under a 10b5-1 plan	−12,500	$30.00	$375K	15,430 direct	Filing · EDGAR
Nov 7, 2008	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			175,000 direct	Filing · EDGAR
Jul 15, 2008	Option or RSU exercised or converted	+12,500	$15.44	$193K	27,930 direct	Filing · EDGAR
Jul 15, 2008	Sale under a 10b5-1 plan	−12,500	$37.50	$469K	15,430 direct	Filing · EDGAR
Jul 15, 2008	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			187,500 direct	Filing · EDGAR
Apr 15, 2008	Option or RSU exercised or converted	+12,500	$15.44	$193K	27,579 direct	Filing · EDGAR
Apr 15, 2008	Sale under a 10b5-1 plan	−12,500	$33.22	$415K	15,079 direct	Filing · EDGAR
Apr 15, 2008	Option or RSU exercised or converted Stock Option (Right to Buy)	−12,500			200,000 direct	Filing · EDGAR
Apr 2, 2008	Sale under a 10b5-1 plan	−2,142	$30.87	$66K	15,079 direct	Filing · EDGAR
Mar 31, 2008	Shares withheld for tax or exercise price	−1,192	$29.03	$35K	11,221 direct	Filing · EDGAR
Mar 31, 2008	Grant or award from the company	+6,000			17,221 direct	Filing · EDGAR
Mar 31, 2008	Grant or award from the company Stock Option (Right to Buy)	+42,000			42,000 direct	Filing · EDGAR
Mar 31, 2008	Grant or award from the company Stock Option (Right to Buy)	+20,000			20,000 direct	Filing · EDGAR
Jan 15, 2008	Option or RSU exercised or converted	+12,500	$15.44	$193K	24,913 direct	Filing · EDGAR

27 earlier transactions are in the filing list below.

Angiotech Pharmaceuticals Director · filings 2008 to 2009

Date	Transaction	Shares	Held after	Source
Dec 10, 2009	Grant or award from the company Stock Option with Tandem SAR	+12,500	42,500 direct	Filing · EDGAR
Jun 10, 2009	Grant or award from the company Stock Option with Tandem SAR	+5,000	30,000 direct	Filing · EDGAR
Dec 8, 2008	Grant or award from the company Stock Option with Tandem SAR	+5,000	20,000 direct	Filing · EDGAR
Dec 8, 2008	Grant or award from the company Stock Option with Tandem SAR	+5,000	25,000 direct	Filing · EDGAR

All 132 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Jun 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 17, 2026	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Jun 12, 2026	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 1, 2026	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Sep 12, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 11, 2025	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 18, 2025	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Jun 13, 2025	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 5, 2025	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 4, 2025	Form 144	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 2, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 2, 2025	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Aug 19, 2024	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 13, 2024	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 12, 2024	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Jun 7, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
May 31, 2024	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 16, 2023	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 14, 2023	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Jun 14, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 14, 2023	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 12, 2023	Form 144	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 7, 2023	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 5, 2023	Form 144	Pacira BioSciences PCRX	Filing · EDGAR
Jun 5, 2023	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Apr 5, 2023	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Apr 3, 2023	Form 144	Pacira BioSciences PCRX	Filing · EDGAR
Jan 17, 2023	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 28, 2022	Form 4	Edgewise Therapeutics EWTX	Filing · EDGAR
Jun 9, 2022	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 8, 2022	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 6, 2022	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 24, 2021	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 11, 2021	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 8, 2021	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 25, 2021	Form 3	Edgewise Therapeutics EWTX	Filing · EDGAR
Nov 17, 2020	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jul 2, 2020	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 25, 2020	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 15, 2020	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 15, 2020	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 11, 2020	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 8, 2020	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jan 8, 2020	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Sep 12, 2019	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 18, 2019	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 17, 2019	Form 3	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 28, 2019	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 17, 2019	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 6, 2019	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
May 31, 2019	Form 4	Dynavax Technologies	Filing · EDGAR
Jan 11, 2019	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jul 30, 2018	Form 4	Aratana Therapeutics	Filing · EDGAR
Jun 15, 2018	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 8, 2018	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 8, 2018	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 1, 2018	Form 4	Dynavax Technologies	Filing · EDGAR
Jan 4, 2018	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 23, 2017	Form 4	Aratana Therapeutics	Filing · EDGAR
Jun 19, 2017	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 16, 2017	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 14, 2017	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 2, 2017	Form 4	Dynavax Technologies	Filing · EDGAR
Jun 28, 2016	Form 4	Aratana Therapeutics	Filing · EDGAR
Jun 20, 2016	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 17, 2016	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 10, 2016	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 8, 2016	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
May 31, 2016	Form 4	Dynavax Technologies	Filing · EDGAR
Oct 14, 2015	Form 4	Dynavax Technologies	Filing · EDGAR
Jun 19, 2015	Form 4	Aratana Therapeutics	Filing · EDGAR
Jun 17, 2015	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 5, 2015	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
May 28, 2015	Form 4	Dynavax Technologies	Filing · EDGAR
Feb 13, 2015	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Feb 10, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Feb 10, 2015	Form 3	Portola Pharmaceuticals	Filing · EDGAR
Feb 9, 2015	Form 3	Dynavax Technologies	Filing · EDGAR
Feb 9, 2015	Form 4	Dynavax Technologies	Filing · EDGAR
Sep 16, 2014	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jul 9, 2014	Form 4	Delcath Systems	Filing · EDGAR
Jun 10, 2014	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 5, 2014	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
May 9, 2014	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Apr 4, 2014	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Feb 6, 2014	Form 4	Aratana Therapeutics	Filing · EDGAR
Feb 5, 2014	Form 3	Aratana Therapeutics	Filing · EDGAR
Jan 17, 2014	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Dec 12, 2013	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Oct 11, 2013	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Sep 12, 2013	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 14, 2013	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 11, 2013	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 7, 2013	Form 4	Delcath Systems	Filing · EDGAR
Jul 9, 2012	Form 4	Delcath Systems	Filing · EDGAR
Jul 9, 2012	Form 3	Delcath Systems	Filing · EDGAR
Jun 11, 2012	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 7, 2012	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Oct 17, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jul 14, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 14, 2011	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 6, 2011	Form 4	Pacira BioSciences PCRX	Filing · EDGAR
Jun 6, 2011	Form 3	Pacira BioSciences PCRX	Filing · EDGAR
Apr 27, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 4, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jan 20, 2011	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Nov 10, 2010	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 15, 2010	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Apr 19, 2010	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 2, 2010	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jan 20, 2010	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 14, 2009	Form 4	Angiotech Pharmaceuticals	Filing · EDGAR
Dec 4, 2009	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jul 24, 2009	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 16, 2009	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Jun 11, 2009	Form 4	Angiotech Pharmaceuticals	Filing · EDGAR
Apr 2, 2009	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jan 20, 2009	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Dec 10, 2008	Form 4	Angiotech Pharmaceuticals	Filing · EDGAR
Nov 10, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jul 17, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 17, 2008	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 5, 2008	Form 4	Acadia Pharmaceuticals ACAD	Filing · EDGAR
May 5, 2008	Form 3	Acadia Pharmaceuticals ACAD	Filing · EDGAR
Apr 16, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 10, 2008	Form 3	Angiotech Pharmaceuticals	Filing · EDGAR
Apr 2, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jan 16, 2008	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Aug 14, 2007	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Apr 2, 2007	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 13, 2006	Form 4	Onyx Pharmaceuticals	Filing · EDGAR
Jun 13, 2006	Form 3	Onyx Pharmaceuticals	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:04 PM ET. The filing on SEC.gov is the record.